NF-L Recombinant Rabbit Monoclonal Antibody [PSH0-77] (HA721498)

UNIPROT #

P07196

PROTEIN NAME

NF-L

SYNONYMS

68 kDa neurofilament protein antibody;68kDa Neurofilament antibody;68kDa neurofilament protein antibody;CMT1F antibody;CMT2E antibody;FLJ53642 antibody;Light molecular weight neurofilament protein antibody;NEFL antibody;Neurofilament light antibody;Neurofilament light polypeptide 68kDa antibody;Neurofilament light polypeptide antibody;Neurofilament protein, light chain antibody;Neurofilament subunit NF L antibody;Neurofilament triplet L protein antibody;NF-L antibody;NF68 antibody;NFL antibody;NFL_HUMAN antibody

SUBCELLULAR LOCATION

Cell projection, axon, Cytoplasm, cytoskeleton.

FUNCTION

Neurofilament light polypeptide, also known as neurofilament light chain, abbreviated to NF-L or Nfl and with the HGNC name NEFL is a member of the intermediate filament protein family. This protein family consists of over 50 human proteins divided into 5 major classes, the Class I and II keratins, Class III vimentin, GFAP, desmin and the others, the Class IV neurofilaments and the Class V nuclear lamins. There are four major neurofilament subunits, NF-L, NF-M, NF-H and α-internexin. These form heteropolymers which assemble to produce 10nm neurofilaments which are only expressed in neurons where they are major structural proteins, particularly concentrated in large projection axons. Axons are particularly sensitive to mechanical and metabolic compromise and as a result axonal degeneration is a significant problem in many neurological disorders. The detection of neurofilament subunits in CSF and blood has therefore become widely used as a biomarker of ongoing axonal compromise. The NF-L protein is encoded by the NEFL gene. Neurofilament light chain is a biomarker that can be measured with immunoassays in cerebrospinal fluid and plasma and reflects axonal damage in a wide variety of neurological disorders. It is a useful marker for disease monitoring in amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, and more recently Huntington's disease. It is also promising marker for follow-up of patients with brain tumors. Higher levels of blood or CSF NF-L have been associated with increased mortality, as would be expected as release of this protein reflects ongoing axonal loss. Recent work performed as a collaboration between EnCor Biotechnology Inc. and the University of Florida showed that the NF-L antibodies employed in the most widely used NF-L assays are specific for cleaved forms of NF-L generated by proteolysis induced by cell death.